Processa Pharmaceuticals, Inc. Common (PCSA)

Price$2.52

Value ScoreD

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-69.04%

Price vs S&P 500 (4W)-7.68%

VGM Score33.56

Market Capitalization$6.93M

All Metrics

Book Value / Share (Quarterly)$0.95

P/TBV (Annual)2.35x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-4.57

Price vs S&P 500 (YTD)-20.66%

Gross Margin (TTM)32.24%

Net Profit Margin (TTM)-2981.25%

EPS (TTM)$-10.90

10-Day Avg Trading Volume0.06M

EPS Excl Extra (TTM)$-10.90

EPS (Annual)$-10.36

ROI (Annual)-243.20%

Gross Margin (Annual)100.00%

Net Profit Margin (5Y Avg)-3230.38%

Cash / Share (Quarterly)$0.63

ROA (Last FY)-173.59%

EBITD / Share (TTM)$-7.82

ROE (5Y Avg)-315.34%

Operating Margin (TTM)-2707.69%

Cash Flow / Share (Annual)$-4.43

P/B Ratio2.73x

P/B Ratio (Quarterly)2.64x

Net Income / Employee (Annual)$-1,130,300

EV / Revenue (TTM)62.97x

Net Interest Coverage (TTM)-54.45x

ROA (TTM)-200.80%

EPS Incl Extra (Annual)$-10.36

Current Ratio (Annual)2.54x

Quick Ratio (Quarterly)0.85x

3-Month Avg Trading Volume0.06M

52-Week Price Return-65.29%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$9.32

P/S Ratio (Annual)1386.09x

Asset Turnover (Annual)1.67x

52-Week High$19.63

Operating Margin (5Y Avg)-1796.65%

EPS Excl Extra (Annual)$-10.36

Tangible BV CAGR (5Y)82.09%

26-Week Price Return-61.11%

Quick Ratio (Annual)2.48x

13-Week Price Return-11.58%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)0.98x

Enterprise Value$5.24M

Asset Turnover (TTM)0.18x

Book Value / Share Growth (5Y)-41.76%

Revenue / Employee (Annual)$0

Inventory Turnover (Annual)1.15x

Pretax Margin (Annual)-6744.00%

Cash / Share (Annual)$2.15

3-Month Return Std Dev105.52%

Gross Margin (5Y Avg)39.43%

Net Income / Employee (TTM)$-1,175,600

ROE (Last FY)-243.20%

Net Interest Coverage (Annual)-72.46x

EPS Basic Excl Extra (Annual)$-10.36

Receivables Turnover (TTM)227.00x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-10.90

Receivables Turnover (Annual)226.80x

ROI (TTM)-281.25%

P/S Ratio (TTM)85.88x

Pretax Margin (5Y Avg)-3012.80%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$9.32

Price vs S&P 500 (52W)-89.65%

Year-to-Date Return-12.50%

5-Day Price Return-0.40%

EPS Normalized (Annual)$-10.36

ROA (5Y Avg)-218.81%

Net Profit Margin (Annual)-6720.00%

Month-to-Date Return-1.56%

Cash Flow / Share (TTM)$-0.81

EBITD / Share (Annual)$-10.68

Operating Margin (Annual)-1336.00%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-314.79%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-10.90

P/TBV (Quarterly)2.35x

P/B Ratio (Annual)1.17x

Inventory Turnover (TTM)1.15x

Pretax Margin (TTM)-2978.85%

Book Value / Share (Annual)$2.17

Price vs S&P 500 (13W)-19.83%

Beta0.99x

Revenue / Share (TTM)$0.00

ROE (TTM)-281.30%

52-Week Low$1.76

vGradeD

mGradeC

vgmGradeD

Show chart for

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.14

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
PCSAProcessa Pharmaceuticals, Inc. Common	D	—	C	$2.52
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Processa Pharmaceuticals is a clinical-stage biopharmaceutical company developing Next Generation Chemotherapy (NGC) oncology treatments by modifying how the body processes existing FDA-approved cancer drugs while maintaining their mechanism of action. The company's pipeline includes three NGC drug candidates: PCS6422 (NGC-Cap), PCS3117 (NGC-Gem), and PCS11T (NGC-Iri).